US Stock Insider Trading | Zai Lab Disclosed 4 Insider Trading Transactions on March 10

K-LinePoet · 2026-03-23T06:39:06+00:00

Zai Dian Pharmaceuticals (ZLAB) disclosed four insider transactions on March 10, 2026. Director Du Ying sold 50,000 shares on March 9 and had previously engaged in multiple buy and sell transactions. Zai Dian Pharmaceuticals specializes in biopharmaceuticals, focusing on addressing medical needs related to diseases such as tumors and autoimmune disorders.

K-LinePoet

2026-03-23 06:39:06

Abstract generation in progress

On March 10, 2026, Zai Lab (ZLAB) disclosed four insider trading transactions. Director Du Ying sold 50,000 shares on March 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Director	Du Ying	March 9, 2026	Buy	100,000	1.74	174,000
March 10, 2026	Director	Du Ying	March 9, 2026	Sell	50,000	19.03	951,500
March 10, 2026	Director	Du Ying	March 6, 2026	Sell	50,000	19.42	971,000
March 6, 2026	Director	Du Ying	March 4, 2026	Sell	14,300	18.78	268,300
March 6, 2026	Director	Du Ying	March 5, 2026	Sell	50,000	19.22	961,000
March 6, 2026	Director	Du Ying	March 4, 2026	Sell	35,700	19.32	689,800
March 6, 2026	Executive	Edmondson Frazor Titus III	March 5, 2026	Sell	15,600	19.06	296,700
March 6, 2026	Director	Du Ying	March 5, 2026	Buy	100,000	1.74	174,000
March 5, 2026	Executive	Amado Rafael	March 3, 2026	Sell	10,000	17.38	173,800
December 18, 2025	Executive	Edmondson Frazor Titus III	December 16, 2025	Sell	8,651	17.14	148,300

[Company Information]

Zai Lab Limited is a biopharmaceutical holding company primarily engaged in the discovery, development, and commercialization of medicines. The company aims to address unmet medical needs in oncology, autoimmune diseases, infectious diseases, and central nervous system disorders. It owns a series of patent candidate drugs from discovery to late-stage clinical development, including Zele, OPTUNE, Qingle, Nuzare, and Weiwei Jia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.